Asthma News and Research

RSS

Asthma is a common inflammatory disease affecting the airways that leads to shortness of breath, coughing and wheezing. Symptoms range from mild to severe but are generally manageable with appropriate treatment.

NHSA and Together Rx Access collaborate to improve prescription access

The National Head Start Association (NHSA) and Together Rx Access announced today a collaboration to launch the Together Rx Access(R) FOR HEAD START Card to help eligible uninsured individuals and families associated with Head Start access immediate and meaningful savings on prescription medicines and products right at their neighborhood pharmacies.

10 Sep 2009

Therapeutic principles of monoclonal antibodies

Professor Joachim R. Kalden, Member of the Department for Molecular Immunology, Nikolaus-Fiebiger-Zentrum, University Medical School Erlangen-Nuremberg, presents therapeutic principles based on monoclonal antibodies.

10 Sep 2009

Merck's GARDASIL receives approval from FDA Advisory Committee

Merck & Co., Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.

10 Sep 2009

American Asthma Foundation awards $750,000 for asthma research

Dr. Serpil Erzurum, one of the nation's leading experts in asthma, has been awarded $750,000 by the American Asthma Foundation (AAF). Dr. Erzurum will collaborate with experts in nuclear medicine and physics to develop an innovative way for clinicians to observe changes in the lungs of patients during an asthma attack.

9 Sep 2009

Caldolor launched ahead of schedule in U.S. by Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it has successfully implemented the U.S. launch of Caldolor((R)), an intravenous formulation of ibuprofen, designed primarily for use in the hospital setting.

9 Sep 2009

Humana Military announces the URAC re-accreditation for its Case Management Program

Humana Military Healthcare Services, a wholly owned subsidiary of Humana Inc. (NYSE: HUM), recently received re-accreditation for its Case Management Program from URAC, a Washington, D.C.-based health care accrediting organization that establishes quality standards for the industry.

9 Sep 2009

Philadelphia MCAN project as model for managing childhood asthma and reducing H1N1 risk

Nearly a dozen 7th graders with asthma were welcomed along with other classmates back to school today by a special guest who had a message for them about staying healthy - Kathleen Sebelius, 21st Secretary of Health and Human Services (HHS).

9 Sep 2009

DOR's Phase 1/2 clinical trial for prevention of radiation enteritis receives NIH grant

DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis.

8 Sep 2009

Benefits of early exposure to daycare not sustainable

New research hints that the common belief that kids who go to daycare have lower rates of asthma and allergy later in life might be nothing more than wishful thinking. While young children in daycare definitely do get more illnesses and experience more respiratory symptoms as a result, any perceived protection these exposures afford against asthma and allergy seem to disappear by the time the child hits the age of eight.

8 Sep 2009

PPA bus tour raises awareness of patient assistance programs

The "Help is Here Express" bus tour will be stopping in Kentucky throughout the week of September 8 - 11 at various cities in order to help uninsured and financially-struggling Kentuckians access information on programs that provide prescription medicines for free or nearly free.

5 Sep 2009

Researchers discover the causes for the severity of RSV illness

Approximately one-half of all infants are infected with the respiratory syncytial virus (RSV) during the first year of life, and almost all children have been infected at least once by the time they reach their second birthday. Researchers at West Virginia University have discovered what makes RSV such a severe and persistent illness.

4 Sep 2009

nSpire Health awarded over $9 million for clinical research trials

nSpire Health, a leading global manufacturer of respiratory diagnostic products and services, announced today clinical trial research services awards of over $9 million in August. The trials awarded by prominent pharmaceutical companies include the company’s eSP™ core lab services, gold standard KoKo® spirometry, and new patent pending PiKoLogic® electronic patient reported outcomes (ePRO) solution.

4 Sep 2009

Positive impact on medication adherence through Aetna's care management program

Aetna announced today results of an analysis from the first half of 2009, demonstrating an average medication adherence of over 95 percent for its members taking Specialty medications. Disease states evaluated in Aetna’s analysis include: multiple sclerosis, rheumatoid arthritis, HIV, Crohn's disease, Pulmonary Arterial Hypertension (PAH), psoriasis, Hepatitis C and asthma.

4 Sep 2009

New treatment for vaso-occlusive crisis in sickle cell patients

GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company that is developing a new class of glycobiology-based therapies for a broad range of indications, today announced that a pilot study of the company’s lead candidate, GMI-1070, is underway in sickle cell patients. The first patients in this pilot study were treated at Children’s Hospital & Research Center Oakland in California.

4 Sep 2009

Brown University neuroscience professor awarded EUREKA grant

Brown University neuroscience professor Gilad Barnea will receive a nearly $1.3 million, four-year federal grant toward development of a method to selectively monitor the activation of each of the five receptors for the neurotransmitter dopamine in the brain.

4 Sep 2009

SAFLUTAN launched in United Kingdom and Spain

Merck Sharp & Dohme (MSD) has launched SAFLUTAN (tafluprost) in the United Kingdom and Spain, and additional launches in other countries are expected over the next several months, pending regulatory approvals, the Company said today.

3 Sep 2009

Damprid's recommendations for tackling seasonal allergy

For America’s 60 million seasonal allergy sufferers, fall can be one of the most difficult times of year as ragweed begins to release its pollen into the air and mold and fungus spores increase due to the decay of leaves and other plants. Each ragweed plant produces one billion pollen grains per average season. This generally continues until the first frost, usually in October.

3 Sep 2009

Aerocrine’s NIOX MINO technology approved in Canada for treating asthma

Aerocrine AB (STO:AEROB) today announced that Health Canada’s Therapeutic Products Directorate has approved Aerocrine’s NIOX MINO® technology for use in treating asthma. Canada’s National Health Service may now begin using the NIOX MINO, a medical device that provides a measure of the degree of inflammation in the airways in a single breath.

3 Sep 2009

Sepracor to be acquired by Dainippon Sumitomo Pharma for $2.6 billion

Dainippon Sumitomo Pharma Co., Ltd. (“DSP”, TSE: 4506) and Sepracor Inc. (“Sepracor”, Nasdaq: SEPR) today announced that they have entered into a definitive agreement pursuant to which DSP will acquire Sepracor for approximately $2.6 billion through a cash tender offer of $23.00 per share, followed by a merger to acquire all remaining outstanding Sepracor shares at the same price paid in the tender offer.

3 Sep 2009

Department of Health Care Services 2009 Gold Quality Award for SFHP

San Francisco Health Plan (SFHP), the City's community public health plan, today announced that it has received the Department of Health Care Services 2009 Gold Quality Award, ranking the plan as a leader in quality care throughout the state of California for Medi-Cal managed care plans.

2 Sep 2009